MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
237 hedge funds and large institutions have $7.67B invested in MyoKardia, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 79 increasing their positions, 78 reducing their positions, and 42 closing their positions.
44% more capital invested
Capital invested by funds: $5.32B → $7.67B (+$2.35B)
38% more funds holding in top 10
Funds holding in top 10: 13 → 18 (+5)
15% more call options, than puts
Call options by funds: $17.7M | Put options by funds: $15.4M
7% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 42
1% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 78
1% more funds holding
Funds holding: 235 → 237 (+2)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$131M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$77.7M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$52M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$48.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$37.2M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$48.9M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$29.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.9M |
| 4 |
BlackRock
New York
|
-$25.8M |
| 5 |
D.E. Shaw & Co
New York
|
-$25.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCV
276
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | -$33K | -345 | Closed |
|
277
ClearBridge Investments
New York
| – | -$20K | -206 | Closed |
|
|
HIA
278
Harbor Investment Advisory
Lutherville,
Maryland
| – | -$1K | -9 | Closed |
|
|
PA
279
Parallel Advisors
San Francisco,
California
| – | -$319 | -3 | -50% |
|
MYOK Hedge Fund Activity: Q3 2020 in Review
237 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q3 2020, worth a combined $7.67B — up 44% from $5.32B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new MYOK positions and 42 closed out — a net gain of 3 holders — while 79 added to existing stakes and 78 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $131M. The largest seller was Janus Henderson Group, cutting an estimated $48.9M.
- 237 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q3 2020, up from 235 in Q2 2020.
- Funds reported $7.67B of MyoKardia, Inc. Common Stock stock for Q3 2020, up 44% quarter-over-quarter.
- 45 funds opened new MyoKardia, Inc. Common Stock positions in Q3 2020 and 42 closed out, a net change of +3 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q3 2020 was T. Rowe Price Associates, an estimated $131M added.
- The largest MyoKardia, Inc. Common Stock seller in Q3 2020 was Janus Henderson Group, an estimated $48.9M sold.
Based on aggregated 13F filings for Q3 2020.